IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo

Margherita Boieri a,b, Aina Ulvmoen b,a, Amanda Sudworth b,a, Clare Lendrem c, Matthew Collin c, Anne M. Dickinson c, Lise Kveberg d, and Marit Inngjerdingen e

*Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; bDepartment of Immunology, Oslo University Hospital, Oslo, Norway; cInstitute of Cellular Medicine, Medical School, Newcastle University, Newcastle-upon-Tyne, UK; dDepartment of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

ABSTRACT
NK cells have shown promise in therapy of hematological cancers, in particular against acute myeloid leukemia. In contrast, the more NK cell-resistant acute lymphoblastic leukemia (ALL) is difficult to treat with NK-cell-based therapies, and we hypothesized that pre-activation of NK cells could overcome this resistance. We show in pediatric and adult patients with T-cell ALL (T-ALL) perturbed NK cell effector functions at diagnosis. Using an in vivo rat model for T-ALL, Roser leukemia (RL), suppressed NK cell effector functions were observed. NK cells from T-ALL patients had reduced expression of the activating receptors NKp46 and DNAM-1, but not NKG2D. In contrast to T-ALL patients, NKGD2 was downregulated on NK cells during rat RL. Decreased frequencies of terminally differentiated NKG2A^CD57^-CD56^dim NK cells in human T-ALL was paralleled in the rat by reduced frequencies of bone marrow NK cells expressing the maturation marker CD11b, possibly indicating impairment of differentiation during leukemia. RL was highly resistant to autologous NK cells, but this resistance was overcome upon pre-activation of NK cells with IL-12, IL-15, and IL-18, with concomitant upregulation of activation markers and activating receptors. Importantly, adoptive transfers of IL-12, IL-15, and IL-18 pre-activated NK cells significantly slowed progression of RL in vivo. The data thus shows that T-ALL blasts normally resistant to NK cells may be targeted by cytokine pre-activated autologous NK cells, and this approach could have potential implications for immunotherapeutic protocols using NK cells to more efficiently target leukemia.

Introduction
NK cells are increasingly attractive for immunotherapies toward cancers.1-3 NK cell effector functions are induced when signals from one or more activating receptors override inhibition through inhibitory receptors binding to MHC class I.4 Ligands for activating NK cell receptors, such as NKG2D, DNAX Accessory Molecule-1 (DNAM-1), and the natural cytotoxicity receptors (NCRs) NKp46 and NKp30 are variably upregulated on malignant cells, rendering them susceptible to NK cells.5 NK cells have been successfully used in the treatment of haematological cancers. In particular, haploidentical KIR-mismatched bone marrow transplantsations,6 or infusions of haploidentical KIR-ligand mismatched NK cells promoted eradication of leukemic blasts in acute myeloid leukemia (AML) patients.7 In contrast, there has been limited success in similar treatments of adult acute lymphoblastic leukemia (ALL) patients, while some success with pediatric patients is reported.8 ALL blasts are generally resistant to NK cells, as they less frequently express ligands for activating NK cell receptors, in combination with normal MHC class I expression levels.9,10 Reduced surface levels of DNAM-1, NKp46, NKp30, and/or NKG2D by NK cells are frequently observed in AML and variably in ALL patients.9,11-14 Low surface expression of activating receptors at diagnosis is correlated with low NK cell activity, poor outcome, and increased risk of relapse.15-19 Reduced NK cell activity is also reported in patients with other haematological disorders, such as chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS).20,21 Reduced NKG2D expression is mediated by both TGF-β as well as soluble NKG2D ligands released from blasts,22,24 but whether NKG2D is directly involved in targeting leukemic blasts is controversial.25 In contrast, reduced expression of DNAM-1 has been directly correlated with inefficient NK cell-mediated killing of malignant cells.26-28

Pre-activation of NK cells with cytokines before infusion has been attempted to enhance tumor clearance. While use of the classical NK-cell activating cytokine IL-2 alone has shown limited success,29 combinatorial pre-activation of NK cells with IL-12, IL-15, and IL-18 has been shown to result in significant tumor regression in a mouse model of lymphoma,30 suppression of graft-versus-host disease in the mouse,31 and, importantly, in a
clinical trial of relapsed or refractory AML. Short-term pre-activation of human or mouse NK cells with IL-12, IL-15, and IL-18 has been shown to result in generation of NK cells with superior effector functions as compared with activation with IL-2 or IL-15 alone. Re-stimulation of these cytokine-activated NK cells leads to enhanced functional activity; hence, NK cells differentiated after IL-12, IL-15, and IL-18 pre-activation was termed cytokine-induced memory-like cells. Their potential utility in immunotherapy is thus obvious.

T-cell ALL (T-ALL) results from a malignancy of T-cell progenitors, representing 15% of pediatric and 25% of adult acute leukemia cases. Significant improvement in intensive risk-adapted chemotherapy protocols have yielded more than 80% 5-y overall survival for pediatric T-ALL patients. Most studies investigating NK cell recognition of ALL have focused on B-ALL, while studies on NK cells and T-ALL are fragmentary. Here, we have addressed the interplay between NK cells and T-ALL, by phenotypic and functional characterization of NK cells in T-ALL patients at diagnosis, and complemented with a rat model for T-ALL, Roser leukemia (RL), to study NK-cell mediated targeting of T-ALL. RL is a radiation-induced leukemia from the PVG rat strain, with similar pathology to human T-ALL. RL primarily infiltrates the spleen upon i.v. injection, but affects several organs at late stages such as the bone marrow, liver, lungs, thymus, testis, and meninges.

We show suppressed NK cell functions during acute T-ALL disease, both in human and in the rat, and show in the rat model that suppressed NK cell functions are extrinsic to the blasts, indicative of suppression mediated by other factors or cells in the environment. Pre-activation of autologous NK cells with IL-15, IL-12, and IL-18 sensitized NK cells to the otherwise highly resistant RL blasts, and upon adoptive transfer in vivo, pre-activated NK cells resulted in significant reductions in RL load. This implies that pre-activation of NK cells is of potential immunotherapeutic use against otherwise resistant T-ALL.

---

**Results**

**Deficient NK cell functions and downregulated expression of DNAM-1 and NKP46 in T-ALL patients**

NK cell effector functions were tested in PBMC obtained at diagnosis from three pediatric T-ALL patients recruited in the period 2014–2016 at Oslo University Hospital, with PBMC from age-matched healthy children as controls. PBMC from another 10 pediatric and 9 adult T-ALL patients recruited at time of diagnosis in the period 1982–1997 were obtained from the Royal Victoria Infirmary in Newcastle, UK. NK cell numbers in the latter samples were too low for functional analysis. Low degranulation, as assessed by surface deposition of the granule marker CD107a, and low IFNγ production in response to the NK cell sensitive tumor target K562 was observed in CD3⁺CD56dim NK cells from pediatric T-ALL patients (Figs. 1A and B). We also observed a reduction in the proportion of CD56⁺ NK cells expressing CD8⁺ in both adult and pediatric patients (Fig. 1C). CD8⁺ NK cells are suggested to represent more functionally active NK cells in terms of both cytotoxicity and cytokine production.

Next, expression of activating and inhibitory NK cell receptors by CD3⁺CD56dim NK cells in pediatric and adult T-ALL patients was compared with healthy children or adults. Reduced frequencies of NKP46⁺ NK cells were observed in the pediatric group, and of DNAM-1⁺ NK cells in both patient groups compared with healthy controls (Fig. 2A). NKP46 expression levels were reduced in both adult and pediatric patients, while DNAM-1 expression levels were reduced in the pediatric patient group only (Fig. 2B). Frequencies and expression levels of NKG2D in NK cells were similar between patients and controls (Figs. 2A and B). NK cells expressing the inhibitory receptors NKG2A and NKR-P1A were present at similar frequencies in patients and controls, but NKR-P1A was expressed at higher levels by NK cells from pediatric patients (Figs. 2A and B).

---

**Figure 1.** Diminished NK cell effector functions in T-ALL patients. PBMC from patients or healthy controls were co-incubated with K562 target cells in the presence of anti-CD107a mAb for 6 h. NK cells were gated as CD14⁻/CD19⁻/CD56dim/CD3⁻ cells, and assessed for (A) degranulation by measuring percentage CD107a⁺ NK cells, or (B) percent intracellular IFNγ expression (n = 3 T-ALL, n = 13 controls, ± SEM). Statistical significance was calculated using the non-parametrical Mann–Whitney test. (C) Frequencies of CD8⁺/CD3⁻/CD56dim peripheral blood NK cells from healthy children or adult controls compared with pediatric or adult T-ALL patients. Data are presented as percentages ± SEM. Statistical significance was calculated using the non-parametrical Mann–Whitney test.
NK cell receptor repertoires are skewed during T-ALL in the rat

A rat model of T-ALL was used to investigate underlying mechanisms of how T-ALL affects NK cells. The leukemia, RL, was injected i.v. and animals killed when blasts reached >30% of PBMC. At this point, the spleen was grossly enlarged. The numbers of NK cells was comparable in blood and spleen in RL and healthy rats (Fig. S1A), but a skewing of NK cell subsets was observed during RL. In the rat, three major NK cell subsets are found. Two of the subsets are mature and fully functional, and express either Ly49s3 or the inhibitory NKR-P1B receptor,42 while a third terminally differentiated NKR-P1B<sup>bright</sup> subset is found in the blood and gut.43 Higher frequencies of NKR-P1B<sup>dim</sup> NK cells were found in both blood and bone marrow in rats with RL, accompanied by reduced proportions of NKR-P1B<sup>bright</sup> cells in the blood (Fig. 3A). The same pattern was observed for total numbers of each subset, though not to statistical significance (Figs. S1B and C). This skewing was not caused by preferential proliferation of NKR-P1B<sup>dim</sup> NK cells (Fig. S1D), suggesting differentiation could be affected.

In the mouse, CD11b and CD27 distinguish immature and mature NK cells.43 This is not as clear in the rat,43 but a skewing toward more CD27<sup>+</sup> and fewer CD11b<sup>+</sup> NKR-P1B<sup>dim</sup> cells was observed in the bone marrow (Fig. S1E). Human NK cells differentiate from CD56<sup>bright</sup> to CD56<sup>dim</sup> NK cells, and further along a pathway with increasing CD57 and decreasing NKG2A frequencies.44,45 At end stage lower frequencies of CD57<sup>+</sup>NKG2A<sup>+</sup> NK cells was found in pediatric T-ALL patients (p = 0.085), with a similar trend for adult T-ALL patients (Fig. S1F), indicating that, as in the rat, NK cell differentiation could be affected.

Reduced NK cell functions and skewing of NK cell receptor repertoire in rats with T-ALL

Similarly to human patients, NK cells from rats with RL showed low degranulation against an NK cell sensitive tumor target (Fig. 3B), and reduced production of IFN<sub>γ</sub> in response to stimulation of activating receptors NKp46, Ly49s3, or NKR-P1A, or in response to IL-12 or IL-18 in combination with IL-2 (Figs. 3C and D). Reduced NK cell functions were not observed at earlier time points when the blast burden was below 2% (Figs. 3B and D).

In contrast to human patients, NKG2D expression was lower in NK cells from spleen, blood, and bone marrow from rats with RL (Fig. 3E), accompanied by reduced frequencies in the spleen (Fig. S2A). Expression levels and frequencies of NKp46<sup>+</sup>, Ly49s3<sup>+</sup>, or NKR-P1A<sup>+</sup> NK cells were similar in healthy and RL rats (Fig. 3F, Fig. S2B, and data not shown). Lack of antibodies toward rat DNAM-1 prevented testing its surface expression. Dnam1 was similarly expressed in NK cells purified from RL or healthy rats, but this was also observed for Nkg2d, indicating post-transcriptional regulation (Fig. S2C). Further analysis of RL indicated limited expression of the NKG2D ligands Rae1l or Rrlt, while these were expressed by the NK cell sensitive rat tumor cell line YB2/0 (Fig. 3G). RL expressed Pvr (CD155), a ligand for DNAM-1, at higher levels than primary T cells (Fig. 3G).

Reduced NK cell functionality and downmodulation of NKG2D in the rat was not directly mediated by the RL blasts. In vitro overnight co-cultures of enriched, autologous splenic NK cells from healthy rats with RL did not affect either degranulation toward YAC-1 or IFN<sub>γ</sub> production in response to IL-12 (Figs. S3A and B), nor NKG2D surface expression upon overnight co-culture of enriched NK cells with RL (Fig. S3A). Moreover, serum concentration of TGF-β was similar in healthy and sick rats (Fig. S3D), and
although RL expressed Tgfβ at higher levels than primary T cells (Fig. S3E), we did not detect elevated TGF-β levels in in vitro cultures of RL alone or with enriched NK cells (Fig. S3F). Moreover, overnight or 5-d cultures of NK cells with serum from rats with RL did not affect IFNγ production or NKG2D expression levels (Figs. S3G and H, and data not shown). This indicates that soluble serum factors are unlikely to directly affect NK cells, although exogenous TGF-β reduced NKG2D expression in vitro (Fig. S3I).

**NK cells pre-activated with IL-15, IL-12, and IL-18 potently kill the resistant RL blasts**

RL are resistant to lysis by autologous, IL-2-activated NK cells. Here, poor degranulation and low cytotoxicity by resting, autologous NK cells in response to RL is shown (Figs. 4A and B). Extending the killing assay from 4 to 20 h led to increased specific lysis of RL independent of Fas/Fas-L (Fig. 4B). Also, conjugate formation between NK cells and RL increased over time (Fig. S4A).
Compared to primary T cells, expression of Trailr2, Fas, and adhesion molecules CD2, CD48, and ICAM-1 was low on RL, while MHC class I was similarly expressed, indicating reduced potential for interaction of NK cells with RL (Figs. S4B and C).

IL-15 in combination with IL-12 and IL-18 is shown to enhance NK cell effector functions and tumor recognition.30,32 We therefore tested targeting of RL by autologous, enriched NK cells from healthy rats pre-treated with either IL-15 alone...
or in combination with IL-12 and IL-18. Heightened activity of NK cells was observed with increased expression of CD25 and CD69, in particular after culture with all three cytokines (Fig. 4D and data not shown). Moreover, increased expression levels of NKG2D, Ly49s, and FasL, but not Nkp46, was observed after pre-activation with IL-15 alone or with IL-12 and IL-18 (Fig. 4D). qRT-PCR analysis showed upregulation of Dnam1 (Fig. 4C). IL-15 pre-activated NK cells demonstrated higher cytolytic activity toward the resistant RL compared with untreated NK cells, which was further enhanced by IL-12, IL-15, and IL-18 pre-activation reaching levels comparable to killing of the sensitive YB2/0 targets by untreated NK cells (Fig. 4D). While lysis of YB2/0 targets was partially reduced by NKG2D antibody blockade, lysis of RL appeared to be independent of NKG2D. This correlates with the expression of NKG2D ligands by YB2/0 but not by RL (Fig. 3G), and suggests that killing of RL by cytokine pre-activated NK cells is mediated by other activating receptor(s), possibly via DNAM-1/CD155.

**IL-15/12/18 pre-activated NK cells slow RL development in vivo**

To test whether IL-12, IL-15, and IL-18 pre-activated NK cells target RL also in vivo, we established a model where rats were initially sub-lethally irradiated at 4 Gy to facilitate engraftment of transfected NK cells. Also, irradiation was previously shown to be necessary for effective tumor clearance by cytokine pre-activated NK cells. Instead, downregulation of NKG2D has been attributed to soluble NKG2D ligands or ligands expressed by extracellular vesicles could mediate Nkp46 downregulation. In contrast, the DNAM-1 ligands CD155 and CD112 are frequently found on T-ALL blasts lacking expression of NKG2D ligands.9,49 Potentially, soluble ligands or ligands expressed by extracellular vesicles could mediate Nkp46 downregulation. In contrast, DNAM-1 ligands CD155 and CD112 are frequently found expressed by malignant cells, and directly linked to receptor downregulation.26,27 DNAM-1 surface expression was not tested in the rat due to unavailability of antibodies, but as CD155 was detected at the mRNA level in RL, we hypothesize that DNAM-1 may be regulated similarly in human and rat T-ALL. We have also observed variable expression of CD155 and CD112 by human T-ALL blasts (unpublished observations). While this points to potential involvement of DNAM-1 in recognition of T-ALL, CD155 also interacts with the inhibitory receptor TIGIT expressed by human and rat NK cells.

The inhibitory NKR-P1A receptor was expressed at higher levels in the pediatric T-ALL patient group. In parallel, increased frequencies NK cells expressing the inhibitory NKR-P1B receptor were observed in rats with RL. The implication of enhanced expression of inhibitory NKR-P1s in unclear at the moment, as is the relationship between human NKR-P1A and the four NKR-P1 members in the rat; activating NKR-P1A and -F, and inhibitory NKR-P1B and -G. The ligand for human NKR-P1A, LLT1, or ligands for rat NKR-P1 receptors—the Clr molecules—are not expressed by T-cell leukemias.50,51 In rats with RL, NKR-P1Bdim bone marrow NK cells contained more CD27–CD11b+ cells than in healthy controls. While CD27–CD11b+ NK cells represent less differentiated cells in mice, CD27 and CD11b are not good maturation markers in the rat. However, bone marrow rat NK cells express less CD11b than peripheral NK cells, indicating that CD11b to a certain extent may predict maturation.43 Also, in T-ALL patients, reduced frequencies of the most differentiated NK cells were
Figure 5. (For figure legend, see page 8).
observed. The human and rat data could suggest an impairment of NK cell differentiation, or alternatively, exhaustion of mature, effector NK cells.

We show that rat autologous NK cells poorly target T-ALL blasts. Previous studies have shown that pre-activating NK cells with combinations of IL-12, IL-15, and IL-18 upregulate activating NK cell receptors, enhance expression of the cytolytic molecules FasL, TRAIL, perforin, and granzyme B, and induce a memory-like phenotype. Further, NK cells upregulate CD25, rendering NK cells more sensitive to IL-2 driven activation and expansion. Accordingly, rat NK cells upregulated CD25 and CD69 in response to IL-12, IL-15, and IL-18, and upregulated surface expression of NKG2D and Ly49s3 and of DNAM-1 mRNA. Importantly, cytokine pre-activated NK cells displayed increased cytotoxicity toward the resistant RL. Blocking NKG2D minimally influenced killing of RL, corroborating the low levels of NKG2D ligands found in RL. Recognition of RL must therefore rely on other activating receptors. Expression of the DNAM-1 ligand CD155 by RL could possibly mediate such recognition. The heightened activity status of NK cells induced by the cytokines may be as important as the increased expression of activation receptors. IL-15 alone or in combination with IL-12 and IL-18 yielded comparable upregulation of activating receptors, but only IL-15, IL-12, and IL-18 pre-activation led to superior NK cell cytotoxicity toward the resistant RL blasts. Cytokine pre-activation could also lead to increased sensitivity by promoting an over-ride of inhibitory input via MHC class I.

Our data show the potential of using pre-activated NK cells for eradication of normally resistant cancers, as reduced burdens of RL was observed in vivo after adoptive transfer of IL-12, IL-15, and IL-18 pre-activated NK cells. Previously, tumor regression after transfer of IL-12, IL-15, and IL-18 pre-activated NK cells was demonstrated in a mouse lymphoma model and in human refractory AML. Although there is a clear effect of infusing pre-activated NK cells, there is an obvious need to improve their efficiency. NK cells persist in vivo, but the heightened expression levels of activation markers and activating receptors are lost within days of transfer. Also, the transferred NK cells delay the disease with only a few days, and improved protocols for pre-activation and for maintaining heightened activity of NK cells in vivo are needed. The latter has been tackled by infusion of low-dose IL-2, but this may be a futile strategy for T-ALL. Instead IL-15 could represent a more optimal strategy. Obtaining sufficient numbers of expanded pre-activated autologous NK cells from cancer patients in a clinical setting is at present technically challenging. These NK cells are also potentially functionally impared, and also face inhibition through self MHC class I expressed by leukemic blasts, although we clearly demonstrate that this latter problem is partly overcome by cytokine pre-activation of NK cells. Alternatively, cytokine pre-activated allogeneic haploidentical NK cells could represent a more feasible approach, as recently demonstrated in a clinical trial of relapsed/refractory AML by Fehninger and colleagues. The use of haploidentical NK cells is safe and more feasible, and not associated with any detrimental graft-vs.-host reactions.

In summary, we show that NK cells are functionally suppressed in T-ALL patients at diagnosis and in rats having RL. We show in the rat model that the suppressed NK functions were not directly mediated by the blasts themselves, or by soluble serum factors, suggesting factors extrinsic to the blasts are responsible. Pre-activating NK cells with IL-15, IL-12, and IL-18 led to efficient targeting and killing of the normally resistant RL both in vitro and in vivo. Further improvements of protocols for NK cell pre-activation could lead to enhanced in vivo activity and improved therapeutic protocols for T-ALL and other haematological cancers.

Materials

Patients and healthy controls

PBMCs were collected at diagnosis and before therapy initiation from 19 patients admitted between 1982 and 1997 at the Royal Victoria Infirmary in Newcastle, UK, and from three patients admitted between 2014 and 2016 at Oslo University Hospital, Oslo, Norway. All were diagnosed with T-ALL. The pediatric group consisted of 13 patients (1–18 y, median age 5.5 y), and the adult group of nine patients (25–48 y, median age 37 y). As controls, PBMCs were obtained from 13 healthy adult controls and 20 healthy children (1–16 y, median age 9.5 y) undergoing elective surgery at Oslo University Hospital. All samples were obtained after informed consent according to the Declaration of Helsinki, and anonymized. The study was approved by the regional ethical committees. For all samples, peripheral venous blood was immediately processed to separate PBMCs.

Animals

Eight to twelve-week-old PVG-R776 (PVG.7B) rats were used. The rats have been maintained at the Department of Comparative Medicine, Institute of Basic Medical Sciences, University of Oslo for more than 20 generations. The Department of Comparative Medicine institutional veterinarian has established the rules for feeding, monitoring, handling, and sacrifice of animals in compliance with regulations set by the Ministry of Agriculture of Norway and "The European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes." The institutional veterinarian has

Figure 5. (see previous page) Adoptive transfer of cytokine pre-activated NK cells reduces RL load. Rats (n = 10) were sub-lethally irradiated at 4 Gy and injected with RL 24 h later. IL-12, IL-15, and IL-18 pre-activated NK cells were adoptively transferred to rats (n = 5) at days 3, 6, and 9. Control rats received no NK cells (n = 5). (A) Spleen weights of rats having RL with (white bars, n = 5) or without (black bars, n = 5) infusion of pre-activated NK cells. (B) Total numbers of RL per mL blood or total numbers of RL per spleen in rats with (white bars, n = 5) or without (black bars, n = 5) infusion of pre-activated NK cells. (C) Percent reduction of RL blasts in spleen, blood, or BM in rats receiving pre-activated NK cells. (D) Donor NK cells (CD45.2+/−) are readily detected in spleen, blood, and BM at sacrifice 4 weeks after RL injection. (E) Total numbers of donor CD45.2+/− NK cells per spleen or per mL blood at sacrifice 4 weeks after RL injection. (F) Percent proliferating Ki67+ host or donor NK cells at sacrifice 4 weeks after RL injection. (G) Expression of FasL, NKG2D, Ly49s3, and Nkp46 on host and donor NK cells at sacrifice 4 weeks after RL injection, presented as RFI values ± SEM. Statistical significance was calculated using the non-parametrical Mann–Whitney test. Data represents two individual experiments with a total five rats in each group.
delegated authority from the Norwegian Animal Research Authority (NARA). The laboratory facilities are subject to a routine health-monitoring program and tested for infectious organisms according to a modification of Federation of European Laboratory Animal Science Associations (FELASA) recommendations. The use of animals for this study was approved by NARA, license number 6010 (in vitro) and 6060 (in vivo). Rats were killed by asphyxiation with CO₂ in a chamber allowing controlled input of gas, to reduce suffering.

**Antibodies and flow cytometry**

Antibodies used were from BD Biosciences anti-rat CD3 (G4.18FITC (cat.no 554832) or-PE (554833)), anti-rat NKR-P1A (10/78PE, cat.no. 555009), anti-mouse CD27-PE (cat.no. 558754), anti-mouse CD11b (WT.5-biotin, cat.no.554981), anti-rat CD54 (1A29-PE, cat.no. 554970), anti-human CD7 (M-T701-PerCP-Cy5.5, cat.no. 561602), anti-human CD8 (SK1-FITC, cat.no. 345772), anti-human CD56 (B159-Alexa647, cat.no. 557711), and Streptavidin-PerCP (cat.no. 554064) from BioLegend anti-human CD3 (OKT3-PE, cat.no. 56-0037-42), anti-human CD14 (M5E2-PerCP-Cy5.5, cat.no. 45-0149-42), anti-human CD19 (1D3-PerCP-Cy5.5, cat.no. 45-0199-42), and anti-human NKG2D (A20-biotin, cat.no. 13-5872); from R&D Systems antirat Fas (goat IgG, cat.no. AF2159) and anti-human DNM-1 (#102511-PE, cat.no. FAB666P); from BioLegend anti-human NKp46 (9E2-BV650, cat.no. 331927); from LifeSpan Biosciences anti-human CD61 (B199.2-biotin, cat.no. LS-C38585); from Beckman Coulter anti-human NKG2A (Z199-PE-Cy7, cat.no. B10246); from Thermo Fisher Scientific Streptavidin-QDot605 (cat.no. Q10101MP), mAbs to rat NKR-P1A (3.2.3), rat Ly49s3/i3/i4 (DAR13), rat NKp46 (Wen23), rat NKR-P1B (STOK27), rat CD2 (OX34), rat CD48 (OX45), rat MHC-1 (OX18), and rat CD45.2 (His41) were generated from hybridomas and conjugated according to standard protocols. Anti-rat NKG2D antibody was a kind gift from Dr S. Krams. Cells were labeled with relevant antibodies and analyzed by Fortessa, LSRII, or FACSCalibur (BD Biosciences). Frozen, human samples were thawed immediately before use, and dead cells were excluded from analysis using the Fixable Viability Dye eFluor780 (eBiosciences, cat.no. 65–0865–14). Lymphocytes (singlets) were gated by forward and side scatter. Rat NK cells were gated as NKR-P1A⁺CD3⁺, and human NK cells as CD56⁺CD3⁺CD14⁺CD19⁺. Data were analyzed using FlowJo software (TreeStar, Ashland, OR).

**Cells and cell cultures**

Human PBMC were processed by either Lymphoprep (Axis-Shield, cat.no. 1114544) or Ficoll (GE Healthcare, cat.no. 17–1440–02), and viability was assessed in liquid nitrogen. Rat mononuclear cells (MNC) from spleen, blood, and bone marrow were prepared by Lymphoprep separation from both rats with end-stage leukemia and from healthy rats. This resulted in 50–60% NKR-P1A⁺CD3⁻ NK cells. The mouse T cell lymphoma cell line YAC-1 (ATCC TIB-160), the rat B lymphoblastic cell line YB2/0 (ATCC® CRL1662™), and the human CML cell line K562 (ATCC® CCL-243™) were maintained in complete RPMI (cRPMI; RPMI supplemented with 10% FBS, 2-ME, sodium pyruvate, and penicillin/streptomycin).

**Enrichment of NK cells and cytokine pre-activation**

Rat NK cells were enriched from mononuclear spleen cells by incubation in nylon wool (PolySciences, cat.no. 18369–50) at 37°C for 45 min, followed by negative selection using a mixture of antibodies toward T cells (R73 and OX19), B cells (OX12 and OX33), monocytes (ED1), and macrophages/granulocytes (OX41), and Pan mouse IgG Dynabeads (Thermo Fisher Scientific, cat.no. 11041). Cytokine pre-activated NK cells were generated by overnight cultures of enriched NK cells with 10 ng/mL IL-12 (Sigma-Aldrich, cat.no. SRP4163), 10 ng/mL IL-15 (PeproTech, cat.no. 400–24), and 50 ng/mL IL-18 (R&D Systems, cat.no. 521–RL-025). Rat NK cells were enriched from mononuclear spleen cells by incubation in nylon wool (PolySciences, cat.no. 18369–50) at 37°C for 45 min, followed by negative selection using a mixture of antibodies toward T cells (R73 and OX19), B cells (OX12 and OX33), monocytes (ED1), and macrophages/granulocytes (OX41), and Pan mouse IgG Dynabeads (Thermo Fisher Scientific, cat.no. 11041).

**Roser leukemia (RL) model**

The radiation-induced T cell lymphoblastic leukemia RL (originating from the PVG strain; CD45.1 allotype) was a gift from Dr Roser, Cambridge, UK. Leukemia was induced by i.v. injection of 4 × 10⁴ RL into the tail vein of rats from the PVG.7B strain (CD45.2 allotype). Propagation of RL injected i.v. occurs primarily in the spleen, but are detected in high numbers in blood and bone marrow during late stages of the disease. The disease was monitored by blood samplings from the tail vein, and RL identified as CD45.1⁺CD3⁺ cells by flow cytometry. The end point was set to 30% RL among PBMCs. Blood, spleen, and bone marrow was collected for analysis at sacrifice. For in vivo targeting by NK cells, rats were sub-lethally irradiated at 4 Gy from an X-ray source (RS320, Xstrahl Life Sciences, UK), followed by injection of RL 24 h later. IL-12, IL-15, and IL-18 pre-activated NK cells were washed four times in PBS, and 4–6 × 10⁶ cells were injected per rat at days 3, 6, and 9. Control rats were injected and injected with RL only. All rats within an experimental series were terminated when blasts reached >30% of PBMC in control rats.

**CD107a degranulation and ⁵¹Cr release assays**

Degranulation by rat NK cells was measured using a hamster anti-rat CD107a antibody generated in our laboratory as described previously. With this antibody 10–15% degranulation is measured against potent target cells. Degranulation by human NK cells were measured by incubating 100 μL PBMC (2 × 10⁶ cells/mL) with 100 μL K562 target cells (2 × 10⁶ cells/mL) in the presence of anti-human CD107a-BV510 (BD Biosciences, cat.no. 560378) for 6 h, with Brefeldin A (Sigma-Aldrich, B7651) added at 5 μg/mL for the last 5 h. NK cell cytotoxicity was measured with a standard ⁵¹Cr release assay, using enriched NK cells as effector cells and ⁵¹Cr-labeled YAC-1, YB2/0, or RL as target cells as described previously. For blocking experiments, blocking antibodies were added at 5 μg/mL. Results are presented as mean values from triplicates for each E:T cell ratio.

**Analysis of intracellular IFNγ and Ki67 expression**

Intracellular IFNγ expression in human NK cells was measured after 6 h of culture of PBMC in the presence of K562 target cells as described above for the degranulation assay. Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.5%
saponin in PBS and 2% FBS for 20 min, and stained with anti-IFNγ (BD Biosciences, cat.no. 554552) for 30 min in permeabilization buffer. Intracellular IFNγ expression in rat NK cells was investigated by flow cytometry after 6 h of incubation as described previously.43 Briefly, enriched NK cells were seeded at 3 × 10^5 cells/well in 96-well plates in the presence of IL-2 (from a CHO cell line stably transfected with a rat IL-2 expression construct), and indicated concentrations of IL-12 (ThermoFischer) or IL-18 (50 ng/mL, R&D Systems), or in wells pre-coated with 10 μg/mL of indicated mAbs. Where indicated, IL-2 were incubated with the enriched NK cells at indicated ratios. GolgiStop (BD Biosciences, cat.no. 554715) was added for the last 5 h of culture. Proliferative activity was measured by intracellular staining of Ki67 using anti-mouse/rat Ki67 (SolA15-PE-Cy7, eBiosciences, cat.no. 14–5698–80) after fixation and permeabilization using the Foxp3/Transcription Factor Staining Buffer Set from ebiosciences (cat.no. 00–5523–00) according to manufacturer’s instruction.

**RNA extraction, cDNA synthesis, and real-time PCR**

NK cells were positively selected from spleen of rats with leukemia or from control rats using Pan Mouse IgG Dynabeads coupled to anti-NKR-P1A antibodies. Total RNA was isolated using the mirVana miRNA Isolation Kit (Thermo Fisher Scientific, cat.no. AM1560) in accordance with the manufacturer’s instructions using RNase-free equipment. RNA concentration and purity was measured by 260:280 and 260:230 ratios (purity measured between 1.8 and 2.0) using NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). To generate cDNA, 2 μg of RNA was mixed with 2 μL random hexamer primers (Thermo Fisher Scientific, cat.no. S0142) and ddH2O up to 15 μL volume and run 10 min at 70°C. One microliter of M-MLV reverse transcriptase (Promega, cat.no. M1701), 5 μL of M-MLV 5x buffer (Thermo Fisher Scientific, cat.no. 18057018), 1 μL RNase inhibitor (Promega, cat.no. N2615), 0.01 M DTT, and 2 μL of 10 mM dNTPs were added for total volume 25 μL and run for 1 h at 37°C. cDNA was stored at −20°C until use. Real-time PCR was performed with Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific, cat.no. 4367659), and run using the 7900HT Fast Real-Time PCR System (Thermo-Fischer), with initial run for 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of denaturation at 95°C (15 sec) and amplification at 60°C (1 min). Melting curves were performed at 95°C (15 sec) followed by 60°C (20 sec) and 95°C (20 sec). Primers were designed using NCBI PrimerBlast, and specificity tested in silico by BLAST. Primers are listed in Table 1. All samples were normalized to Cd45 expression. Expression levels are reported as log transformation of 2^ΔCt (Log_RQ).

**Conjugate assay**

Enriched splenic NK cells were labeled with 0.5 μM CFSE (Thermo Fisher Scientific, cat.no. C1157) at 3 × 10^5 cells/mL in PBS and 2% FBS for 10 min at 37°C, and anti-NKR-P1A Alexa647. Target cells (YAC-1 or RL) were stained with semi-naphthazarinfluor (SNARF-1) (Thermo Fisher Scientific, cat. no. C1270) according to the manufacturer’s protocol. 100 μL enriched NK cells (3 × 10^5 cells) were mixed with 100 μL target cells (3 × 10^5 cells) with an effector to target ratio 1:1, spun for 30 sec at 300 g, and incubated at 37°C for 2, 10, 60, or 120 min. Reactions were stopped by addition of 2% paraformaldehyde. As negative control target and effector cells were mixed after fixation. Conjugate formation was analyzed by flow cytometry, and percentage of NKR-P1A+ NK cells in conjugates with target cells calculated.

**ELISA**

Serum samples were obtained at sacrifice and stored at −80°C until use. Supernatants were obtained after overnight co-culture of RL with enriched splenic NK cells at different RL:NK cell ratios, and stored at −20°C until use. Concentrations of TGF-β in serum and cell culture supernatants were measured in duplicates using the Quantikine ELISA kit for Mouse/Rat/Porcine/Canine TGF-β1 (R&D Systems, cat.no. MB100B) following the manufacturer’s instructions. Samples were activated for 10 min with 1N HCl and neutralized with 1.2N NaOH/0.5M HEPES. Serum samples were diluted 1:60 before assay. Absorbance was read at 450 nm, and concentrations interpolated from a standard curve.

**Statistical analysis**

Graphics and statistical analysis were performed with the GraphPad Prism software. Data are presented as the mean ± standard error of the mean (SEM). Statistical significance was calculated using the non-parametrical Mann–Whitney U test or the Kruskal–Wallis test. p values less than 0.05 were considered statistically significant.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Funding**

This work was supported by The South-Eastern Norway Regional Health Authority under grant 2013068, the European Union under grant FP7-PEOPLE-2012-ITN-315963 (CELLEUROPE), and Anders Jahres fond til vitenskapes fremme. The authors thank Dr Ke-Zheng Dai and Ulla Hegeland for technical assistance.

---

**Table 1. List of primers.**

| Gene     | Primer sequence 5′-3′ | Accession ID |
|----------|-----------------------|--------------|
| B2m      | F: GAGCGAGTGGCTCCACAGGT | NM_012512.2  |
|          | R: CAAGCTTGGAGACGAGTGGA | AF251010     |
| Cd45     | F: CCGGGTITGCCTGTGTCCTCTT | NM_00107370  |
|          | R: CTTCTGGCTTTCCTGTGTCCTT | NM_013512    |
| Cd226    | F: CTCGTAAGCCAGACATCAGGCA | NM_00116619  |
|          | R: AAGCTGGCAACTGACTTGA   | NM_017067    |
| Klrk1    | F: GTTGGAGCTCTGTTGACAGCC | NM_021578    |
|          | R: ACCAAACACGCGCTGTATT  |              |
| Raetl1   | F: CCTTACCGTAGATGAGAAGCA |              |
|          | R: CTTTAAGCTGTCGTTATATC |              |
| Pvr      | F: AACTATAGCTGGAGACGCCGCGC |              |
|          | R: ACCAAACACGCGCTGTATT  |              |
| Tgbf1    | F: AGGCTTACGATCGACACTTC |              |
|          | R: CCACCGTATGACGATGCGCCG |              |
| Trailr2  | F: TCTCATGCAGCATATGGTGC  | NM_00110873.1|
|          | R: CCCGGTTGAGACGACCCTT  |              |
References

1. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7:329-39; PMID:17438573; http://dx.doi.org/10.1038/nri2073

2. Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploring the First Line of Defense Against Cancer. Cancer J 2015; 21:486-91; PMID:26588681; PMCID:26264743; http://dx.doi.org/10.1097/PPO.0000000000000156

3. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17:1025-36; PMID:27570492; http://dx.doi.org/10.1038/ni.3518

4. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Ann Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-070505

5. Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer blood and bone marrow mononuclear cells from patients with childhood acute lymphoblastic leukemia. Acta Paediatr Scand 1985; 74:433-7; PMID: 3859177; http://dx.doi.org/10.1111/j.1651-2227.1985.tb01998.x

6. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozzioc-nacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A. Defec-tive expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99:3661-7; PMID:11986221; http://dx.doi.org/10.1182/blood.V99.10.3661

7. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996; 10:478-82; PMID:8642605

8. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de LH, Sarvaria A et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014; 99:836-47; PMID:24488563; http://dx.doi.org/10.3324/haematol.2013.087536

9. Lowdell MW, Craston R, Samuel D, Wood ME, O’Neill E, Saha V, Prentice HG. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117:821-7; PMID:12606116; http://dx.doi.org/10.1046/j.1365-2141.2002.03495.x

10. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX et al. BCR- ABL oncogene directly controls MHC class I chain-related mole-cule A expression in chronic myelogenous leukemia. J Immunol 2006; 176:3108-16; PMID:16585609; http://dx.doi.org/10.4049/ jimmunol.176.8.5108

11. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109:4816-24; PMID:17341666; http://dx.doi.org/10.1182/blood-2006-07-03559

12. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172:7335-40; PMID:15187109; http://dx.doi.org/10.4049/jimmunol.172.12.7335

13. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, Jr., Chatterjee SK. Inhibition of NK cell activity through TGF-β1 by down-regula-tion of NKG2D in a murine model of head and neck cancer. J Immunol 2006; 176:5541-50; PMID:16210663; http://dx.doi.org/10.4049/jimmunol.175.8.5541

14. Crane CA, Han SJ, Barry JJ, Atni BJ, Lanier LL, Parsa AT. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009

15. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activat-ing immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019

16. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Sol-ana R, Tarazona R. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2011; 89:109-15; PMID:21383766; http://dx.doi.org/10.1080/11754601.2011.15

17. Carlsten M, Norell H, Brysson YT, Poschke I, Schvedins K, Ljung-ren HG, Kiessling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009; 183:4921-30; PMID:19801517; http://dx.doi.org/10.4049/jimmunol.0901226
31. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209:2351-65; PMID:22309317; http://dx.doi.org/10.1084/jem.20120944

38. G Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S et al. NK-cell subset expresses an activated CD25 phenotype and is prevalent in blood, liver, and gut-associated lymphoid organs of rats. J Immunol 2012; 188:2499-508; PMID:22308308; http://dx.doi.org/10.4049/jimmunol.1003939

44. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Björklund AT, Flodström-Tullberg M, Michaelsson J, Rottenberg ME et al. Expression patterns of NKG2A, KIR, and CD57 define a progeny of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64; PMID:20696944; http://dx.doi.org/10.1182/blood-2010-04-281675

48. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 2004; 60:153-8; PMID:15238084; http://dx.doi.org/10.1111/j.0300-9475.2004.01436.x

61. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Rebecchi M, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585

64. Stegmann KA, De Souza JB, Riley EM. IL-18-induced expression of high-affinity IL-2 receptor on human cytotoxic CD56dimCD16+ NK-cell subset. Blood 2010; 116:3865-74; PMID:20733159; http://dx.doi.org/10.1182/blood-2010-04-282301

68. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585

71. Nestvold J, Stokland A, Naper C, Rolstad B. Phenotype and natural killer cell sensitivity of a radiation-induced acute T-cell leukaemia (Roser leukaemia) in PVR rats. Scand J Immunol 2004; 60:153-8; PMID:15238084; http://dx.doi.org/10.1111/j.0300-9475.2004.01436.x

74. De Veirman K, Van Valkenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 2014; 4:4349; PMID:25538893; http://dx.doi.org/10.3389/fonc.2014.00349

77. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 2004; 60:153-8; PMID:15238084; http://dx.doi.org/10.1111/j.0300-9475.2004.01436.x

80. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585

83. Stegmann KA, De Souza JB, Riley EM. IL-18-induced expression of high-affinity IL-2 receptor on human cytotoxic CD56dimCD16+ NK-cell subset. Blood 2010; 116:3865-74; PMID:20733159; http://dx.doi.org/10.1182/blood-2010-04-282301

86. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585

89. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585

92. Yu X, Harden K, Gonzalez LC, Francesco M, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105:3615-22; PMID:15657183; http://dx.doi.org/10.1182/blood-2004-07-2585